Brief: Expedeon Signs Deal With Abcam For Sale Of Its Immunology And Proteomics Business

2Invest AG

11/11/2019 07:39

Nov 11 (Reuters) - EXPEDEON AG  EXNG.DE :
    * PURCHASE PRICE IS EQUIVALENT TO TWICE EXPEDEON'S CURRENT
MARKET
CAPITALIZATION OR MORE THAN 9-TIMES 2018 ANNUAL GROUP REVENUE
    * SIGNS EUR 120 MILLION DEAL WITH ABCAM FOR SALE OF ITS
IMMUNOLOGY
AND PROTEOMICS BUSINESS
    * EXPEDEON AG WILL RETAIN APPROXIMATELY 38 % OF ITS ASSETS
AT
LEVEL OF INDIVIDUAL FINANCIAL STATEMENTS AND 15 % AT LEVEL OF
CONSOLIDATED FINANCIAL STATEMENTS
    * AGREEMENT COVERS SALE AND TRANSFER OF ALL SHARES IN
EXPEDEON
HOLDINGS LIMITED (CAMBRIDGE, UK), ORGANISED IN THREE DIVISIONS
    * AGREEMENT IS SUBJECT TO SHAREHOLDER APPROVAL AT AN
EXTRAORDINARY
MEETING OF EXPEDEON AG TO BE HELD IN HEIDELBERG ON DECEMBER
19TH, 2019

Source text for Eikon:  ID:nEQbNnR3Ya 
Further company coverage:  EXNG.DE 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))